IP Library Granted Patent US 7,071,183
Granted Patent B2
US 7,071,183 · App. 10/206,659 · Granted Jul 4, 2006

Use of inhibitors of the renin-angiotensin system

Assignee: Ark Therapeutics Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,071,183
App. No.
10/206,659
Granted
Jul 4, 2006
Kind
B2
Abstract

It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

Claims (2)

1. A method for the treatment of cancer cachexia, wherein said method comprises administering to a person or animal in need of such treatment a lipophilic inhibitor of the renin-angiotensin system; and wherein the inhibitor of the rennin-angiotensin system is an inhibitor of angiotensin-coverting enzyme (“ACE”).

2. The method, according to claim 1 , wherein the ACE inhibitor is selected from the group consisting of quinapril, captopril, lisinopril, peridopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril lisinopril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, cilazapril, delapril, enalaprilat, fosinopril, moveltiprqil and trandolapril.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2022
From: PHARMACEUTICAL PATENT ATTORNEYS, LLC
To: TRIZELL LTD., F/K/A FINVECTOR LTD. F/K/A ARK THERAPEUTICS LTD.
Reel/Frame 058826/0044 →
SECURITY INTEREST Recorded Nov 19, 2020
From: TRIZELL LTD.
To: PHARMACEUTICAL PATENT ATTORNEYS, LLC
Reel/Frame 054775/0546 →
CHANGE OF NAME Recorded May 16, 2019
From: ARK THERAPEUTICS, LTD.
To: FINVECTOR VISION THERAPIES LTD.
Reel/Frame 049198/0414 →
CHANGE OF NAME Recorded May 16, 2019
From: FINVECTOR VISION THERAPIES LTD.
To: TRIZELL LTD.
Reel/Frame 049198/0498 →
CHANGE OF NAME Recorded Jul 14, 2003
From: EUROGENE LIMITED
To: ARK THERAPEUTICS LIMITED
Reel/Frame 013797/0292 →
Priority Claims (2)
GB 9722026.3 · Oct 17, 1997 · national
GB 9810855.8 · May 20, 1998 · national
Continuity (4)
Continuation 0952962800
Provisional Application 6006781900 · Dec 5, 1997
Provisional Application 6009490200 · Jul 31, 1998
Related Publication 20020187939A1 · Dec 12, 2002